Depixus will be participating in the 20th Anniversary of the Discovery on Target Conference from 25 to 28 September, 2023, Boston, USA.

Discovery on Target (DOT) highlights advances in current and emerging “hot” targets and technologies, as well as target validation strategies for the discovery and development of novel therapeutic agents ranging from biologics to small molecules.

We look forward to meeting you there!

Dr Jimmy Ouellet, Chief Scientist at Depixus, participated in the 9th NovaLix Conference ‘Biophysics in Drug Discovery’, from 26 — 28 April, in Philadelphia. Dr Ouellet presented a poster entitled ‘Single molecule analysis of nucleic acid structure — small molecule interaction and molecular dynamics using MAGNA™’.

Dr Christine Blancher, Head of Applications & Collaborations and Dr Zhen Wang, Principal Scientist at Depixus, participated in the CHI Drug Discovery Conference section on ‘RNA-Targeting Small Molecule Drugs’, from 11 — 12 April, in San Diego. They presented posters entitled ‘MAGNA™: single molecule real-time analysis of dynamic nucleic acid interactions’ and ‘Single molecule analysis of nucleic acid structure — small molecule interaction and molecular dynamics using MAGNA™’, respectively.

Gordon Hamilton MD, CEO, participated in the RNA Leaders Europe Congress in Basel, 15 – 16 March, presenting a poster entitled ‘MAGNA™: single molecule real-time analysis of dynamic nucleic acid interactions’. We discuss how our state-of-the-art technology platform, MAGNA™ can be used to study complex biomolecular interactions between nucleic acids and small molecules, a topic that is gathering significant excitement in the pharmaceutical industry.

MAGNA™ can be used to study complex biomolecular interactions between nucleic acids and small molecules, a topic that is gathering significant excitement in the pharmaceutical industry.